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Abstract: The purpose of this article is to study the pros and cons of glucocorticoids in anti-inflammatory effects and to
evaluate them. Because inflammation can play a positive role in removing pathogens and recovering the body on the one
hand, it can also bring about adverse reactions such as redness, swelling, heat, and pain. Therefore, understanding the pros
and cons of glucocorticoids in anti-inflammatory effects has the guiding significance in the clinical drug use.
Based on the complexity of the clinical effects of glucocorticoids on the patient’s body, this article first analyzes the
specific symptoms of inflammation, which are mainly manifested as redness, swelling, heat, pain, and dysfunction, and then
analyzes the mechanism of inflammation, which is mainly due to body fluid leakage and the role of cytokines.
Then, based on the symptoms and mechanism of inflammatory episodes, the inflammatory episodes are divided into
fatal and non-fatal attacks, and three dosage regimens are designed. On this basis, the three dosage regimens were evaluated
in the treatment of fatal and non-fatal seizures from four indicators of safety, effectiveness, stability, and uniformity, and the
following evaluation results were obtained.
In the treatment of fatal diseases, the evaluation weight of the A program is 0.587384, the evaluation weight of the B
program is 0.202727, and the evaluation weight of the C program is 0.209809. In the treatment of non-fatal diseases, the
evaluation weight of the A plan is 0.5462, the B plan is 0.261573, and the C plan is 0.192148.
Analyze the three programs in the fatal disease situation and the non-fatal disease situation respectively, and draw the
experimental conclusion that the comprehensive evaluation result of the A program is better than the B and C programs
whether it is to treat fatal or non-fatal diseases. In the treatment of fatal diseases, the C program is slightly better than the B
program, and in the treatment of non-fatal diseases, the B program is better than the C program.
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1. Introduction
1.1 The background of the topic and its significance
Inflammation is a physical sign that the body shows when it is stimulated by damage factors. On the one hand, the
inflammatory reaction is the body's elimination of damage factors in the body to restore the body to normal, and on the other
hand, it will cause redness, swelling, heat, pain, dysfunction and other adverse reactions.
Inflammation has a variety of pathogenic factors, such as bacteria, viruses, strong acids and bases. Mild inflammation is
generally treated by directly eliminating the cause and relying on the patient's own immunity, such as local scalds and cuts.
Severe inflammation generally requires the combination of anti-inflammatory drugs while eliminating the cause to reduce the
damage to the body by inflammation. For example, in the treatment of acute bacterial infections, it is necessary to use
antibiotics together with glucocorticoid anti-inflammatory drugs. However, for acute inflammatory episodes caused by
viruses without antiviral drugs, due to the lack of effective treatment drugs for the cause, anti-inflammatory drugs are
generally used for symptomatic treatment to relieve symptoms, such as the SARS virus in 2003 and the recent new
coronavirus.
Therefore, in the treatment of such viral infections, on the one hand, it is necessary to prevent excessive use of
anti-inflammatory drugs, thereby overly inhibiting the body’s self-repair function, on the other hand, it is necessary to prevent
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insufficient use of anti-inflammatory drugs, which may cause serious adverse inflammatory reactions to the body’s organs.
damage. In this case, the dosage of anti-inflammatory drugs is particularly important.
1.2. Research methods and ideas
Before evaluating the anti-inflammatory effects of glucocorticoids, it is necessary to understand the specific
pathogenesis of inflammation and the effects of glucocorticoids involved in it. On this basis, the analytic hierarchy process is
used to evaluate the anti-inflammatory effects of glucocorticoids from four perspectives: safety, effectiveness, compliance,
and economy.
2. Mechanism of inflammation
First of all, when pathogens or other stimuli appear in the body, the body's first response is to produce an immune
response against the pathogen. On the one hand, the immune system eliminates the pathogen, and on the other hand, it will
cause red, swelling, heat, pain, and dysfunction. Immune response can be divided into innate immunity and specific immunity,
and specific immunity can be divided into cellular immunity and humoral immunity. This article mainly analyzes the
influence of the two factors of body fluid exudation and cytokines on the immune function in the process of inflammation.
2.1 Fluid exudation
On the one hand, the exudation of body fluids can promote the elimination of pathogens, and on the other hand, it can
cause a series of adverse reactions. The therapeutic effect is embodied in three aspects: the role of body fluid itself, the
exudation of white blood cells, and the auxiliary effect of cytokines. The adverse reactions are embodied in redness, swelling,
heat, pain, and dysfunction.[1]
Figure 1 Humoral exudation
Because cytokines are substances that are released by lymphocytes and other cells that can regulate other inflammatory
cells, inflammatory cells need to exudate with body fluids to the site of inflammation in order to have an effective
anti-pathogen effect. It can be said that body fluids exudation is indispensable in the process of cytokine function.
2.2 The role of cytokines
Cytokines are substances secreted by immune cells that can enhance immune function. There are many types of
cytokines. This article mainly introduces the role of interleukin (IL), tumor necrosis factor (TNF) and interferon (IFN) in
inflammation.
The role of cytokines can be divided into direct action and indirect action. The direct action is to achieve the elimination
of pathogens by increasing immunity, such as promoting the proliferation of immune cells, or by stimulating the immune
cells themselves to enhance their ability to fight pathogens. It is functionally Enhance immune function. The indirect effect is
to affect the elimination of pathogens through non-immune influencing factors, such as promoting hematopoiesis, and laying
a good environment for immune function.[4]
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Interleukin was originally thought to be secreted by white blood cells, but now it is a type of cytokine secreted by other
cells. The direct role of interleukin is to promote the proliferation and differentiation of immune cells and enhance innate
immunity and adaptive immunity. The indirect effect is that white blood cells can also promote hematopoiesis. The actual
effect is the same as the exudation of body fluids, laying the environment for the immune system to function.
The role of tumor necrosis factor is mainly direct action, which can eliminate pathogens by enhancing innate immunity
and directly killing tumor cells.
The effect of interferon is also a direct effect, which can eliminate pathogens through direct anti-virus and enhancement
of innate immunity
In the course of clinical use, glucocorticoids mainly inhibit the effects of cytokines.
2.3 Analytic Hierarchy Process Evaluation
2.3.1 The establishment of plans and indicators
The interaction between glucocorticoids and inflammatory diseases is more complicated. The evaluation of the clinical
use of glucocorticoids here mainly considers the anti-inflammatory and anti-immune effects of glucocorticoids, which are
important for safety, effectiveness, economy, and the four indicators of compliance are weighted separately and then
evaluated. There are three main evaluation schemes:
Plan A: Use glucocorticoids plus effective drugs
Plan B: No drugs are used
Plan C: Use only glucocorticoids
Table 1 Judgment matrix of each index weight
Safe Effective Compliance Economic
Safe 1 1 2 6
Effective 1 1 2 6
Compliance 1/2 1/2 1 3
Economic 1/6 1/6 1/3 1
Through calculation, the weight of each indicator is obtained
Table 2 The weight of each indicator
Safe Effective Compliance Economic
Weights 0.3960 0.3960 0.1476 0.0603
2.3.2. Judgment matrix for different indicators
(1) Safety evaluation
On the one hand, A program can control the damage of symptoms to the body, on the other hand, it can eliminate
pathogens by using antibacterial drugs in the process of suppressing immunity to prevent further deterioration of the disease,
so it is safer than B and C programs.
Plan B and Plan C need to be analyzed in different situations in terms of safety. It is necessary to consider whether
inflammatory symptoms are fatal. When the inflammatory symptoms do not induce fatal diseases, because plan B does not
suppress the immune system, the disease can be controlled more quickly. It can prevent further deterioration of the condition
and is safer. But if inflammatory symptoms can induce fatal diseases, then the C program will be much safer.
Table 3 Safety evaluation for the treatment of non-fatal diseases
Plan A Plan B Plan C
Safety evaluation 0.6232 0.2395 0.1373
Table 4 Safety evaluation for the treatment of fatal diseases
Plan A Plan B Plan C
Safety evaluation 0.7272 0.0909 0.1819
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(2) Effectiveness evaluation
The evaluation of effectiveness, compliance, and economics has no obvious relationship with whether it will cause fatal
diseases, so it is no need to classify.
It is believed that the therapeutic drugs used are better than the own immune system in terms of effectiveness. Plan C
uses only glucocorticoids, which will suppress immunity, so it is not as effective as Plan A and Plan B.
Table 5 Evaluation of the effectiveness of treatment of diseases
Plan A Plan B Plan C
Effectiveness evaluation 0.5714 0.2857 0.1429
(3) Compliance evaluation
Compliance is mainly analyzed from the patient's own treatment experience during the entire treatment process. Since
both plan A and plan C use glucocorticoids and are symptomatic treatments, both treatments are better than plan B.
Table 6 Evaluation of the Compliance of treatment of diseases
Plan A Plan B Plan C
Compliance evaluation 0.4286 0.1429 0.4286
(4) Economic evaluation
The economy is mainly considered from the price of drugs. Glucocorticoids and antibacterial drugs are under the
protection of medical insurance, and the clinical use price is relatively low, and the economics are comparable.
Table 7 Evaluation of the economy of treatment of diseases
Plan A Plan B Plan C
Economic evaluation 0.4286 0.1429 0.4286
Summarize the weight of each index evaluation, and get the following two tables
Table 8 Evaluation of indicators for treatment of fatal diseases
Weights Plan A Plan B Plan C
Safe 0.3960 0.7272 0.0909 0.1819
Effective 0.3960 0.5714 0.2857 0.1429
Compliance 0.1476 0.4286 0.1429 0.4286
Economic 0.0603 0.1638 0.5390 0.2973
Table 9 Evaluation of indicators for treatment of non-fatal diseases
Weights Plan A Plan B Plan C
Safe 0.3960 0.6232 0.2395 0.1373
Effective 0.3960 0.5714 0.2857 0.1429
Compliance 0.1476 0.4286 0.1429 0.4286
Economic 0.0603 0.1638 0.5390 0.2973
3. Evaluation results of anti-inflammatory effects of glucocorticoids
Calculate Table 8 to get the final evaluation results of each program
Table 10 Evaluation results of various programs for the treatment of fatal diseases
Plan A Plan B Plan C
Evaluation results 0.587384 0.202727 0.209809
Table 10 Evaluation results of various programs for the treatment of non-fatal diseases
Plan A Plan B Plan C
Evaluation results 0.5462 0.261573 0.192148
It is concluded from the experiment that whether program A is to treat fatal or non-fatal diseases, the comprehensive
evaluation results are better than those of program B and C. In the treatment of fatal diseases, program C is slightly better
than program B. For non-fatal diseases, plan B is better than plan C.
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